Revolution Medicines shared on LinkedIn:
“We’re pleased to share that we have started treating patients in RASolve 308, our global Phase 3 clinical trial evaluating our investigational RAS(ON) G12D-selective inhibitor in combination with standard of care pembrolizumab plus platinum-based chemotherapy doublet as a first-line treatment in patients with metastatic RAS G12D non-squamous non-small cell lung cancer (NSCLC).
RAS mutations are among the most common oncogenic drivers in NSCLC, occurring in approximately 30% of cases.”
՛Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options.՛ – Alan Sandler, Chief Development Officer, Revolution Medicines
Other articles about Zoldonrasib and NSCLC on OncoDaily.
